DNDN
Dendreon

Analyst Conference Call: May 8, 2014 @ 6:00 AM Pacific Time

Dendreon Ready For A Rebound [March 25, 2014 @ Seeking Alpha]
Mary Huber, who cast doubt on Provenge, fined by SEC [12/04/2013 at kfgo.com]
Provenge Approved in Europe [September 17, 2013 press release]
Dendreon Revenue and Cost Trends [August 13, 2013]
Provenge Revenue Trends [January 8, 2013]

older commentary and news is below the analyst conference summary tables

Quarterly Analyst Conference Summaries and Financial Results available:

2014
Dendreon analyst conference summary Q1 2014
 
 
 
05/08/2014
 
 
 
Q1 2014
 
 
 
2013
Dendreon analyst conference summary Q1 2013
Dendreon analyst conference summary Q2 2013
Dendreon analyst conference summary Q3 2013
Dendreon analyst conference summary Q4 2013
05/09/2013
08/08/2013
11/12/2013
03/03/2014 
Q1 2013
Q2 2013
Q3 2013
Q4 2014
2012
Dendreon analyst conference summary Q1 2012
Dendreon analyst conference summary Q2 2012
Dendreon analyst conference summary Q3 2012
Dendreon analyst conference summary Q4 2012
05/07/2012
07/30/2012
11/02/2012
02/25/2013
Q1 2012
Q2 2012
Q3 2012
Q4 2012
2011
Dendreon analyst conference summary Q1 2011
Dendreon analyst conference summary Q2 2011
Dendreon analyst conference summary Q3 2011
Dendreon analyst conference summary Q4 2011
05/02/2011
 08/03/2011
11/02/2011 
02/27/2012 
Q1 2011
 Q2 2011
 Q3 2011
Q4 2011  
2010
Just a Dendreon Press Release  
Dendreon analyst conference summary Q2 2010
Dendreon analyst conference summary Q3 2010
Dendreon analyst conference summary Q4 2010
3/10/2010 
08/03/2010 
 11/03/2010
03/01/2011 
 Q1 2010
Q2 2010  
Q3 2010  
 Q4 2010
2009
Dendreon analyst conference summary Q1 2009
Dendreon analyst conference summary Q2 2009
Dendreon analyst conference summary Q3 2009
Dendreon analyst conference summary Q4 2009
3/12/2009
 08/11/2009
 11/11/2009
 02/22/2010
Q4 2008
Q2 2009  
 Q3 2009
Q4 2009  
2008
Dendreon Q4 2007 analyst conference summary
Dendreon Q1 2008 summary
Dendreon analyst conference summary Q2 2008
Dendreon q3 2008 results
3/13/2008
05/08/2008
08/12/2008
11/7/2008
Q4 2007
Q1 2008
Q2 2008
Q3 2008
2007
DNDN analyst conference summary Q3 2007
DNDN Q2 2007 summary
DNDN summary
11/15/2007
08/07/2007
05/10/2007
11/08/2006
Q3 2007
Q2 2007
Q1 2007
Q4 2006
2006
DNDN analyst conference summary Q3 2006
DNDN analyst conference summary Q2 2006
08/08/2006
05/09/2006
Q3 2006
Q2 2006

Dendreon Gets Provenge Recommendation in Europe [June 28, 2012]
Dendreon Provenge Could See Survival Benefit Extension [April 18, 2013]
Dendreon on the Ropes [November 23, 2012]
Robust Sipuleucel-T Immune Activity Is Detailed in Pooled Data Analysis [October 24, 2012 @ OncLive]
Dendreon Provenge Sales Wobble in Q2 [August 17, 2012]
Dendreon's Boring Q1 Results [May 7, 2012]
Provenge Whitepaper: Immunotherapy: Personalized Treatment for Advanced Prostate Cancer
Dendreon Provenge Challenged Again [April 2, 2012]
Dendreon Announced Q4 Revenues [press release January 5, 2012]
Dendreon Capitulation [November 4, 2011]
Real World Report on Prescribing Provenge [October 9, 2011 at SeekingAlpha]
Dendreon Restructuring Call [September 8, 2011]
Dendreon Provenge Demand Questioned [August 8, 2011]
Dendreon Ramps up Provenge Production [July 15, 2011]
Medicare Will Pay For Provenge [March 30, 2011 New York Times]
Medicare's Provenge Proposal Memo
Dendreon Permitted to Quadruple Provenge Capacity [March 11, 2011, Dendreon press release]
Dendreon Update on Provenge in Europe, Bladder Cancer Treatment [January 7, 2011]
Dendreon Faces Provenge Review - Stock Halted [November 16, 2010, Bloomberg]
Dendreon First Provenge Revenue [August 8, 2010]

Data Point: FDA Cellular, Tissue and Gene Therapies Advisory Committee March 29, 2007 Draft Advisory Committee Questions on Provenge (Sipuleucel-T). This gives both the questions and the basic trial data that was submitted. This committee later recommended that the FDA approve Provenge, but the FDA instead issued an approvable letter.

Data Point: Minutes of FDA Cellular, Tissue and Gene Therapies Advisory Committee March 29-30, 2007 Draft Advisory Committee meeting on Provenge

Dendreon's Medical Coverage Conundrum [July 1, 2010, Adam Feuerstein at TheStreet analysis of CMS situation]
Is the Dendreon Sky Falling? [June 22, 2010]
Dendreon Provenge Approval Calms the Waters [May 11, 2010]
Waiting for the FDA, With Dendreon [February 23, 2010]
Analyst Day Summary [September 24, 2009]
Dendreon, the glory and the dream [June 23, 2009]
Dendreon Sells More Stock [Dendreon Press Release May 13, 2009]
Provenge Data Released to Analysts; Meets Prespecified Endpoint [April 28, 2009]
Provenge Demonstrates Statistically Significant Overall Survival [April 14, 2009]
Dendreon Gets Good Provenge Prostate Cancer Interim Results [October 6, 2008]
Dendreon Press Release on First Quarter 2009 results [May 6, 2009]
Dendreon Provenge Prostate Cancer Results Due Soon [September 14, 2008]
Provenge Interim Data Expected October 2008 [July 23, 2008]
Waiting for Provenge [March 13, 2008]
Nature Biotechnology editorial on FDA's Provenge decision [January 2008]
CareToLive [The prostate cancer patients' site, who are pushing for approval of Provenge and an investigation of the FDA]
Dendreon Breast Cancer Results [August 19, 2007]
Summary of Conference re Latest FDA meeting [May 31, 2007]
Dendreon: There and Back Again [May 11, 2007]
Doctor Voices Dendreon Doubt [Forbes.com, April 26, 2007]
Dendreon Approvable Letter for Provenge [May 9, 2007]
What Price Dendreon? [April 12, 2007]
Dendreon Odds Less Long [March 30, 2007]

Dendreon is a biotechnology company specializing in creating immunotherapies for cancers. At this time its leading product, Provenge, has been approved for marketing in the United States for castrate-resistant, metastatic prostate cancer.

Dendreon Web site:

main page
investor page

Disclaimer: My analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. Before making or terminating an investment you should always verify any factual basis of your decision from multiple independent sources.